CALML5 and cancer: CALML5 methylation was observed in 31/42 (73.8%) of all samples, in 8/8 (100%) pre-treatment samples, in 8/9 (88.9%) cancer-bearing samples, and in 2/8 (25.0%) of the final samples in the series.